Dr. Bryan Richardson is a scientific advisor and patent agent working in the biotech, medical, biochemical, and pharmaceutical arts. He focuses his practice on patent preparation and prosecution for small molecules, pharmaceutical formulations, diagnostic technology, and medical devices. Bryan also advises clients preparing for inter partes review proceedings before the Patent Trial and Appeal Board. He regularly conducts patentability searches, freedom-to-operate studies for clients, and provides patent portfolio valuation for mergers and acquisition as well as joint development and licensing agreements. He represents a broad range of clients, including both generic and branded pharmaceutical companies, universities, and start-ups.
Prior to working for Brinks Gilson and Lione, Bryan earned his doctorate degree from the Department of Pharmacology at the University of North Carolina. His research involved the study of the faulty Rho GTPase signaling mechanisms underlying the cerebrovascular disorder cerebral cavernous malformation (CCM) by using a broad range of cutting edge biotechnology techniques. His research further generated new induced pluripotent stem cell based methods for modeling this disease in cells from human patients affected by CCM.
This advanced technical background gives him unique insights not only into the science behind his clients’ products, but also how to best protect their valuable innovations. Bryan’s goal is to partner with his clients to develop the most useful patent strategy early on that will secure robust patents, which will withstand litigation, post-grant review, and any other challenges.